Amantadine, oseltamivir and zanamivir for the treatment of influenza

  • Technology appraisal guidance
  • TA168
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The assessment report for this appraisal was prepared by the Centre for Reviews and Dissemination, University of York.

  • Burch J, Paulden M, Conti S et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation, July 2008.

The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Manufacturers, or sponsors, and professional or specialist and patient or carer groups were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Alliance Pharmaceuticals (amantadine)

  • GlaxoSmithKline (zanamivir)

  • Roche Products (oseltamivir)

Professional or specialist and patient or carer groups:

  • Diabetes UK

  • British Paediatric Respiratory Society

  • British Thoracic Society

  • Health Protection Agency

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Pathologists

  • Royal College of Physicians

  • Royal Pharmaceutical Society

Other consultees

  • Cornwall and the Isles of Scilly Primary Care Trust

  • Department of Health

  • Dudley Primary Care Trust

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal)

  • British National Formulary

  • Cancer Care Cymru

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Welsh Kidney Patients Association

  • NHS Centre for Reviews and Dissemination and Centre for Health Economics, York

  • National Coordinating Centre for Health Technology Assessment

The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer or sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on NICE's technology appraisal guidance on flu treatment by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Will Carroll, Consultant Paediatrician, nominated by the British Paediatric Respiratory Society Research Committee – clinical specialist

  • Dr Wei Shen Lim, Consultant Respiratory Physician, nominated by the Health Protection Agency – clinical specialist

  • Dr Maria Zambon, Clinical Expert, nominated by the Health Protection Agency – clinical specialist

ISBN: 978-1-4731-6517-5